Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Rapport Therapeutics and Recordati Industria Chimica E Farmaceutica, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rapport Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
| Recordati Industria Chimica E Farmaceutica | 0 | 1 | 0 | 1 | 3.00 |
Rapport Therapeutics currently has a consensus price target of $68.36, suggesting a potential upside of 148.23%. Given Rapport Therapeutics’ higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Recordati Industria Chimica E Farmaceutica.
Risk & Volatility
Rapport Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500.
Valuation & Earnings
This table compares Rapport Therapeutics and Recordati Industria Chimica E Farmaceutica”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rapport Therapeutics | $20.00 million | 66.07 | -$145.85 million | ($3.04) | -9.06 |
| Recordati Industria Chimica E Farmaceutica | $2.96 billion | 4.10 | $501.92 million | $2.80 | 21.00 |
Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Rapport Therapeutics and Recordati Industria Chimica E Farmaceutica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rapport Therapeutics | N/A | N/A | N/A |
| Recordati Industria Chimica E Farmaceutica | 18.38% | 33.73% | 12.76% |
Summary
Recordati Industria Chimica E Farmaceutica beats Rapport Therapeutics on 7 of the 12 factors compared between the two stocks.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
